Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid–poly-l-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy. Issue 2 (3rd January 2015)

• Record Type: Journal Article
• Authors: Miller, Elizabeth; Spadaccia, Meredith; Sabado, Rachel; Chertova, Elena; Bess, Julian; Trubey, Charles Mac; Holman, Rose Marie; Salazar, Andres; Lifson, Jeffrey; Bhardwaj, Nina
• Is Part Of: Vaccine. Volume 33:Issue 2(2015)
• Page Start: 388
• Page End: 395
• Publication Date: 2015-01-03
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2014.10.054
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">Autologous AT-2 inactivated HIV can be derived from donor CD4+ T cells for use a DC vaccine immunogen.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">This immunogen can be generated in GMP laboratories without highly specialized equipment.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">AT-2 HIV-pulsed DCs matured with Poly-ICLC secrete IL-12 and induce HIV-specific immunity.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">This formulation is now approved for investigational use in ART-suppressed individuals.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">This formulation may enhance anti-viral immunity beyond previous therapeutic DC vaccine trials.</p> </list-item> </list> </p> </sec> </abstract>